Patient Satisfaction With Appearance, Scar Outcome and Quality of Life After Skin Cancer Surgery
1 other identifier
observational
3,000
1 country
5
Brief Summary
The purpose of this study is to evaluate patient satisfaction and quality of life as it relates to skin cancer surgery. This research study involves taking a one-time survey online.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Apr 2018
Longer than P75 for all trials
5 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 6, 2018
CompletedFirst Submitted
Initial submission to the registry
April 11, 2018
CompletedFirst Posted
Study publicly available on registry
April 19, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
April 1, 2027
May 6, 2026
May 1, 2026
9 years
April 11, 2018
May 4, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
number of patients satisfied with facial appearance
Satisfaction with Facial Appearance Scale, Appearance-related Psychosocial Distress Scale and Adverse Effects Checklist using the FACE-Q Skin Cancer instrument.
1 year
number of patients satisfied with scar outcome
Appraisal of Scars Scale, Appearance-related Psychosocial Distress Scale and Adverse Effects Checklist using the FACE-Q Skin Cancer instrument.
1year
Eligibility Criteria
At MSK potential participants will be identified as having undergone surgery/ treatment for the treatment of a cutaneous malignancy on the face or patients will be recruited in the clinic when they present for consultation or the day of skin surgery/ treatment.
You may qualify if:
- Patients ≥ 18 years of age at the time of surgery.
- Had a diagnosis of a cutaneous malignancy
- Cutaneous malignancy includes, but is not limited to basal cell carcinoma, squamous cell carcinoma, and melanoma
- Able to speak and read English
- MSK Only Cross Sectional Study: Radiation therapy patients ≥ 18 years of age who have received RT for skin cancer
You may not qualify if:
- Unable to speak and read English
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (5)
UC Davis Comprehensive Cancer Center
Sacramento, California, 95817, United States
Brigham and Women's Hospital (Data Collection Only)
Boston, Massachusetts, 02115, United States
University of Nebraska Medical Center
Omaha, Nebraska, 68198-7680, United States
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
University of Texas Southwestern Medical Center at Dallas
Dallas, Texas, 75390, United States
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Erica Lee, MD
Memorial Sloan Kettering Cancer Center
Study Design
- Study Type
- observational
- Observational Model
- CASE CROSSOVER
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 11, 2018
First Posted
April 19, 2018
Study Start
April 6, 2018
Primary Completion (Estimated)
April 1, 2027
Study Completion (Estimated)
April 1, 2027
Last Updated
May 6, 2026
Record last verified: 2026-05